학술논문

Immune Responses to Varicella-Zoster Virus Vaccines.
Document Type
Academic Journal
Author
Levin MJ; Departments of Pediatrics and Medicine, University of Colorado Denver School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.; Weinberg A; Departments of Pediatrics, Medicine, and Pathology, University of Colorado Denver School of Medicine, Anschutz Medical Campus, Aurora, CO, USA. adriana.weinberg@cuanschutz.edu.
Source
Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0110513 Publication Model: Print Cited Medium: Print ISSN: 0070-217X (Print) Linking ISSN: 0070217X NLM ISO Abbreviation: Curr Top Microbiol Immunol Subsets: MEDLINE
Subject
Language
English
ISSN
0070-217X
Abstract
The live attenuated varicella vaccine is intended to mimic the tempo and nature of the humoral and cell-mediated immune responses to varicella infection. To date, two doses of varicella vaccine administered in childhood have been very effective in generating varicella-zoster virus (VZV) immune responses that prevent natural infection for at least several decades. After primary infection, the infecting VZV establishes latency in sensory and cranial nerve ganglia with the potential to reactivate and cause herpes zoster. Although, the immune responses developed during varicella are important for preventing herpes zoster they wane with increasing age (immune senescence) or with the advent of immune suppression. Protection can be restored by increasing cell-mediated immune responses with two doses of an adjuvanted recombinant VZV glycoprotein E vaccine that stimulates both VZV-and gE-specific immunity. This vaccine provides ~85-90% protection against herpes zoster for 7-8 years (to date).
(© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.)